By Miriam Humbe
Africa is no exception to chronic diseases like diabetes, hypertension, and cardiovascular disorders which are on the rise.
For instance, in Nigeria, 29% of all deaths results from non-communicable diseases, which is driven by lifestyle changes and dietary shifts.
With grappling healthcare systems amidst challenges, innovative health solutions are emerging to transform the way these conditions are managed.
At the forefront of this revolution in pharmaceutical technology is Murli Krishna Pharma Pvt. Ltd, with its modified releases pellets set to make significant impact at WHX Lagos 2025, West Africa’s largest healthcare event.
The Challenge of Chronic Disease Management…
Chronic Disease Management often requires patients to take medications consistently over a long period of time. In most cases traditional medications or dosages forms, such as immediate- release tablets, can lead to fluctuations in drug levels in the bloodstream, with reduced efficacy and increased side effects. Moreover, many patients struggle with the inconvenience of frequent dosing, leading to poor compliance and suboptimal health outcomes.
Advantages of Modified Release Pellets…
Murli Krishna Pharma Pvt Ltd (MKPPL) has pioneered the development of modified release pellets—tiny, spherical pharmaceutical formulations designed to release medication gradually over time.
These pellets offer several advantages over conventional tablets and capsules:
Sustained and Controlled Drug Release: Modified release pellets steadily release medication, maintaining therapeutic levels in the blood for extended periods.
Reduced Side Effects: By avoiding peaks and troughs in drug concentration, these formulations minimize side effects and improve patient comfort.
Improved Compliance: With less frequent dosing required, patients are more likely to follow their treatment period.
Versatility: Pellets can be formulated with a wide range of active pharmaceutical ingredients (APIs), making them suitable for various chronic conditions.
Murli Krishna Pharma: A Legacy of Innovation…
Founded in 2004 under the leadership of Dr. Satya Vadlamani, Murli Krishna Pharma has established itself as a leader in pharmaceutical innovation, particularly in the field of advanced drug delivery systems (DDs). MKPPL’s research and development (R&D) team are dedicated to developing high-quality, patient-centric products that meet international standards, including those set by EU-GMP, WHO-GMP, and Indian FDA guidelines.
One of the company’s standout achievements is the development of aqueous-based matrices for pellet formulations.
This approach eliminates the need for harmful organic solvents, resulting in safer and more environmentally friendly products. Murli Krishna Pharma’s commitment to high quality and healthcare innovation has earned it recognition from global pharmaceutical giants and regulatory authorities alike. For more information on Murli Krishna Pharma Pvt Ltd, please visit the official website: https://www.murlikrishnapharma.com/
Modified Release Pellets: A Closer Look…
Among Murli Krishna Pharma’s portfolio are products like Diclofenac Sodium SR Pellets and Dexlansoprazole DDR Pellets, both of which give the benefits of modified release technology.
Diclofenac Sodium SR Pellets: These are designed for sustained release, providing prolonged anti-inflammatory effects and pain relief, which is especially valuable for patients with chronic conditions like arthritis.
Dexlansoprazole DDR Pellets: Featuring a dual release mechanism, these pellets release the drug into two phases at different pH levels, ensuring optimal absorption and efficacy for managing acid-related disorders.
The technology involved in these pellets allows for precise control on the drug release profiles, suitable for the needs of specific patient populations and disease states.
Showcasing MKPPL’s Healthcare Innovation at WHX Lagos 2025…
WHX Lagos, scheduled for June 2-4, 2025, is the largest healthcare exhibition in West Africa, with over 7000 attendees, 500+ global exhibitors and 100+ influential speakers. This makes it a central hub for networking, learning and business opportunities in the healthcare sector.
WHX Lagos 2025 is expected to showcase innovations across 8 major healthcare product categories, like medical devices, laboratory diagnostics, digital health care, pharmaceuticals, and wellness solutions. This platform will be perfect for collaborations and knowledge sharing.
Murli Krishna Pharma’s participation at WHX Lagos underscores its commitment to advancing healthcare in Africa. By introducing its modified release pellets to the West African market, the company aims to address the unique challenges faced by patients and healthcare providers in managing chronic diseases.
Why Modified Release Matters for Africa?
Africa’s healthcare scenario is rapidly changing, with a rising burden of chronic diseases and limited access to specialist care in many regions. Modified release pellets offer a practical solution by:
Reducing the Frequency of Dosing: This is particularly important in areas where regular access to healthcare facilities may be limited.
Enhancing Treatment Outcomes:
Steady drug levels improve the effectiveness of therapy and reduce complications.
Supporting Health System Efficiency:
Improved compliance and better disease control can reduce the need for hospitalization and emergency care.
MKPPL’s Commitment to Quality and Accessibility…
Murli Krishna Pharma’s manufacturing facilities are accredited by international bodies such as EU-GMP, WHO-GMP, and Indian FDA guidelines, ensuring that all products meet the highest standards of quality and safety. The manufacturing plants have been audited and approved by major international regulators.
MKPPL is also dedicated to making its innovative formulations accessible and affordable, particularly
Modified Release Pellets to Improve Health and Quality Life.
The introduction of modified release pellets by Murli Krishna Pharma (MKPPL) at WHX Lagos 2025 this June, is a significant step forward in chronic disease management for West Africa.
With a deep commitment to patient well-being and the application of advanced pharmaceutical technology, MKPPL is shaping a transformative future where chronic diseases can be managed more effectively, safely, and conveniently.
With the initiatives from Africa, and the continuous evolving of healthcare systems, innovations from Murli Krishna Pharma will play a transformative role in improving the health outcomes and initiating quality of life to millions in the region. The revolution in chronic disease management is just beginning, and the world is watching as Africa takes bold steps toward a healthier future.
Frequently Asked Questions…
Who is Murli Krishna Pharma Pvt Ltd?
Murli Krishna Pharma Pvt Ltd is an Indian pharmaceutical company specializing in advanced drug delivery systems like pellets, micro-pellets, and granules. Established in 2004 by Dr. Satya Vadlamani, the company is known for its innovative, high-quality products and has approvals from major international regulatory bodies.
What is Modified Release Pellets?
Modified Release Pellets are tiny, spherical forms of medicine designed to release drugs slowly and steadily in the body over time. This helps maintain a consistent level of medication, reducing the need for frequent dosing and improving patient comfort.
Does Modified Release Pellets cure Chronic Diseases?
Modified Release Pellets do not cure chronic diseases, but they help manage symptoms by providing controlled and sustained medication release. This leads to better disease control and makes it easier for patients to stick to their treatment plans.
What are the approvals for Modified Releases Pellets?
Modified Release Pellets from Murli Krishna Pharma are manufactured in facilities approved by the European Union, WHO, GCC, and Jordanian FDA. These approvals ensure the products meet strict international quality and safety standards.
Can Modified Releases Pellets solve Chronic Diseases in Africa?
Modified Release Pellets cannot completely solve chronic diseases, but they can greatly improve how these diseases are managed in Africa by making treatment easier and more effective.
Their steady drug release and reduced dosing frequency can help patients achieve better health outcomes.
